A Doctor’s perspective on linaprazan glurate’s unique potential
Highlights from the 2024 Annual Report: Interview with Dr. Prateek Sharma.
Dr. Prateek Sharma, Medical Advisor and expert in gastrointestinal diseases and cancer, shares his insights on its safety and potential usage areas.
Dr. Sharma is a world-renowned physician, teacher, and educator heavily engaged in clinical research activities who has been at the forefront of improving the diagnosis and management of gastrointestinal diseases and cancer, specifically in advanced imaging and endoscopic treatments. He is the President of the Fellow of the American Society for Gastrointestinal Endoscopy.
”The ability of linaprazan glurate to effectively suppress gastric acidity is extraordinary. I want to highlight its clinically important role in the healing of open wounds like erosive esophagitis, which remains sub-optimally treated with current standard therapies (below 50% healing rates in severe cases with PPIs). Linaprazan glurate has a rapid onset of action and demonstrates up to 24-hour maintenance of pH above 4, which is a far longer duration than comparable PCABs (and PPI’s). This efficacy, according to Dr. Sharma is likely to improve patient outcomes and support the healthcare system by streamlining treatment strategies.”
"PCABs like linaprazan glurate have been used clinically in Japan and other parts of Asia for over five years without significant side effects. Short-term data on linaprazan glurate indicate a strong safety profile, making it suitable for acute therapy and healing for all stages of erosive GERD, including severe cases."
Professor Sharma also sees more potential areas of use:
”Linaprazan glurate could also serve as a diagnostic tool for reflux disease. By quickly suppressing acid, it offers a trial-based approach to differentiate acid-related symptoms from other causes. This strategy reduces the need for extensive endoscopic monitoring, streamlining diagnosis and improving patient care.”
He mentions another area: the treatment of Helicobacter pylori infections.
“In combination treatment, acid suppression is key to increasing the effect of antibiotics. The use of linaprazan glurate could enhance eradication rates compared to current therapies. As antibiotic resistance continues to rise, the increased efficacy of linaprazan glurate in this context could significantly improve treatment outcomes.” Prateek concludes.